Global Invasive Ductal Carcinoma Treatment Market
2024 Research: Global Invasive Ductal Carcinoma Treatment Market Set to Reach $23.02 Billion by 2034, - Rising Prevalence of Breast Cancer Fuels Advancements in Personalized Medicine
January 27, 2025 04:29 ET | Research and Markets
Dublin, Jan. 27, 2025 (GLOBE NEWSWIRE) -- The "Invasive Ductal Carcinoma Treatment Market by Therapy, by Type, by Distribution Channel, and By Region" report has been added to ...
Oncology Based in-Vivo CRO Market
Oncology Based in-Vivo CRO Business Research Report 2024: Global Market to Reach $2.5 Billion by 2030 - Expansion in Drug Discovery, Translational Research, and Toxicology Fuels Growth
January 09, 2025 04:01 ET | Research and Markets
Dublin, Jan. 09, 2025 (GLOBE NEWSWIRE) -- The "Oncology Based in-Vivo CRO - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for...
22157.jpg
Oncology-Based In-Vivo CRO Market Projected for Vigorous Growth, North America Leads Regional Shares
March 07, 2024 12:09 ET | Research and Markets
Dublin, March 07, 2024 (GLOBE NEWSWIRE) -- The "Oncology-based In-Vivo CRO Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. Global Industry Anticipates Major...
Bionano_RGB.png
American College of Medical Genetics and Genomics Includes OGM in Latest Edition of Technical Laboratory Standards for Solid Tumor Analysis
February 22, 2024 08:00 ET | Bionano Genomics
SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that optical genome mapping (OGM) was included for the first time in the American College of...
Global Immuno-oncology Clinical Trials Market
Immuno-oncology Clinical Trials Market Poised for Remarkable Growth, with USD 12.87 Billion Forecasted by 2030
January 24, 2024 08:54 ET | Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Global Immuno-oncology Clinical Trials Market by Design (Expanded Access Trials, Interventional Trials, Observational Trials), Phase (Phase I, Phase...
22157.jpg
Anti-Cancer Monoclonal Antibodies Market to Reach $95.99 billion by 2028, with Asia Pacific Emerging as Fastest-Growing Region
January 22, 2024 21:08 ET | Research and Markets
Dublin, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The "Anti-Cancer MAbS Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The Anti-Cancer Monoclonal Antibodies (MAbs)...
Global Oncology-Based In-Vivo CRO Market
Oncology Based In-Vivo CRO Industry Experiences Surge with Innovative Solutions: Global Market Report 2023 Explores Trends and Growth Factors
December 11, 2023 04:28 ET | Research and Markets
Dublin, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The "Oncology Based In-Vivo CRO Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global market for...
Cellectis Logo.png
Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
October 31, 2023 16:30 ET | Cellectis Inc.
NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) --  Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Large-Cell and Other Lung Cancer in the United States: Patient Journey Infographic for All Race/Ethnicity Groups in 2022
Machine Learning Model Unveils Stunning Lung Cancer Risk Predictions
October 05, 2023 11:58 ET | Research and Markets
Dublin, Oct. 05, 2023 (GLOBE NEWSWIRE) -- In a recent groundbreaking study published on October 3rd in the open access journal PLOS Medicine, Thomas Callender of University College London and his...
Emergen logo.png
Global Minimal Residual Disease (MRD) Market Size to Reach USD 4,138.5 Million in 2030 | Emergen Research
September 14, 2023 09:51 ET | Emergen Research
Vancouver, Sept. 14, 2023 (GLOBE NEWSWIRE) -- The global Minimal Residual Disease (MRD) market size was USD 1,095.3 Million in 2021 and is expected to register a revenue CAGR of 16.04% during the...